(Q34274031)

1 August 2017

title

A systematic review on the role of anticonvulsants in the treatment of acute bipolar depression (English)

1 reference

1 August 2017

1 reference

1 reference

Psychiatry and Mental health

domain-ontology-based fuzzy-powered named-entity recognition matcher

5 February 2022

determination method

1 reference

Pharmacology

5 February 2022

domain-ontology-based fuzzy-powered named-entity recognition matcher

1 reference

8

1 reference

1 August 2017

Eduard Vieta

9

0 references

Xénia Gonda

7

object named as

Xenia Gonda

0 references

Adriane R Rosa

object named as

Adriane R Rosa

2

0 references

author name string

María Reinares

1

1 reference

1 August 2017

Carolina Franco

3

1 reference

1 August 2017

José Manuel Goikolea

4

1 reference

1 August 2017

Kostas Fountoulakis

5

1 reference

1 August 2017

Melina Siamouli

6

1 reference

1 August 2017

publication date

10 May 2012

1 reference

The International Journal of Neuropsychopharmacology

1 August 2017

published in

1 reference

1 August 2017

volume

16

1 reference

1 August 2017

issue

2

1 reference

1 August 2017

page(s)

485-496

1 reference

Subsyndromal depressive symptoms are associated with functional impairment in patients with bipolar disorder: results of a large, multisite study.

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000491

7 January 2021

Lamotrigine: when and where does it act in affective disorders? A systematic review

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000491

7 January 2021

Prevalence and characteristics of undiagnosed bipolar disorders in patients with a major depressive episode: the BRIDGE study

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000491

7 January 2021

Diagnostic criteria for bipolarity based on an international sample of 5,635 patients with DSM-IV major depressive episodes

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000491

7 January 2021

Bipolar depression: overview and commentary

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000491

7 January 2021

Carbamazepine in manic-depressive illness: a new treatment

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000491

7 January 2021

Divalproex sodium versus placebo in the treatment of acute bipolar depression: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000491

7 January 2021

Clinical and neurocognitive predictors of functional outcome in bipolar euthymic patients: a long-term, follow-up study.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000491

7 January 2021

The role of mood stabilisers in the treatment of the depressive facet of bipolar disorders

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000491

7 January 2021

A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000491

7 January 2021

A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000491

7 January 2021

A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000491

7 January 2021

A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000491

7 January 2021

A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000491

7 January 2021

Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000491

7 January 2021

Chronic administration of mood stabilizers upregulates BDNF and bcl-2 expression levels in rat frontal cortex

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000491

7 January 2021

Divalproex in the treatment of bipolar depression: a placebo-controlled study

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000491

7 January 2021

Time spent with symptoms in a cohort of bipolar disorder outpatients in Spain: A prospective, 18-month follow-up study

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000491

7 January 2021

An update of evidence-based treatment of bipolar depression: where do we stand?

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000491

7 January 2021

Treatment of bipolar disorder: a systematic review of available data and clinical perspectives

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000491

7 January 2021

Effects of mood stabilizers on hippocampus BDNF levels in an animal model of mania

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000491

7 January 2021

A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000491

7 January 2021

Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000491

7 January 2021

Subsyndromal depressive symptoms after symptomatic recovery from mania are associated with delayed functional recovery

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000491

7 January 2021

The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the treatment of acute bipolar depression

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000491

7 January 2021

Evidence-based guidelines for treating bipolar disorder: revised second edition--recommendations from the British Association for Psychopharmacology

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000491

7 January 2021

Maintenance efficacy of divalproex in the prevention of bipolar depression

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000491

7 January 2021

A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000491

7 January 2021

The long-term natural history of the weekly symptomatic status of bipolar I disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000491

7 January 2021

International Consensus Group on the evidence-based pharmacologic treatment of bipolar I and II depression

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000491

7 January 2021

Metabolism and excretion of mood stabilizers and new anticonvulsants

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000491

7 January 2021

Topiramate versus bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder: a preliminary single-blind study

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000491

7 January 2021

Effect of number of episodes on wellbeing and functioning of patients with bipolar disorder.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000491

7 January 2021

Clinical practice recommendations for bipolar disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000491

7 January 2021

Acute efficacy of divalproex sodium versus placebo in mood stabilizer-naive bipolar I or II depression: a double-blind, randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000491

7 January 2021

Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000491

7 January 2021

New treatment guidelines for acute bipolar depression: a systematic review

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000491

7 January 2021

Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD).

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000491

7 January 2021

Number needed to treat analyses of drugs used for maintenance treatment of bipolar disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000491

7 January 2021

Antidepressant effects of carbamazepine

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000491

7 January 2021

Functional impairment and disability across mood states in bipolar disorder.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000491

7 January 2021

Levetiracetam in the management of bipolar depression: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000491

7 January 2021

Randomized, double-blind pilot trial comparing lamotrigine versus citalopram for the treatment of bipolar depression

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000491

7 January 2021

Valproate for the treatment of acute bipolar depression: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000491

7 January 2021

Influence of sub-syndromal symptoms after remission from manic or mixed episodes

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000491

7 January 2021

Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000491

7 January 2021

Efficacy and Safety of Lamotrigine as Add-On Treatment to Lithium in Bipolar Depression

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000491

7 January 2021

Efficacy and safety of two treatment algorithms in bipolar depression consisting of a combination of lithium, lamotrigine or placebo and paroxetine

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000491

7 January 2021

Long-term outcome of bipolar depressed patients receiving lamotrigine as add-on to lithium with the possibility of the addition of paroxetine in nonresponders: a randomized, placebo-controlled trial with a novel design.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000491

7 January 2021

Efficacy and acceptability of mood stabilisers in the treatment of acute bipolar depression: systematic review

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000491

7 January 2021

Topiramate for acute affective episodes in bipolar disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000491

7 January 2021

Treatment options for bipolar depression: a systematic review of randomized, controlled trials

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000491

7 January 2021

Evolving trends in the long-term treatment of bipolar disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000491

7 January 2021

Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000491

7 January 2021

Adjunctive herbal medicine with carbamazepine for bipolar disorders: A double-blind, randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000491

7 January 2021

10.1017/S1461145712000491

Identifiers

DOI

1 reference

1 August 2017

1 reference